Silence Therapeutics plc, a biotechnology company, engages in the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Silence Therapeutics Plc

An update from Soluna Holdings ( ($SLNH) ) is now available. On December 9, 2025, Soluna Holdings announced its November 2025 business updates, hig...

Soluna Holdings Reports November 2025 Business Updates

Top Piper Sandler analyst Yasmeen Rahimi left the firm’s recent Healthcare Conference with stronger confidence in several biotech names heading int...

CRNX, CYTK, MDGL, SLNO: Top Analyst Outlines Her ‘Top Biotech Ideas for 2026’

Soluna Holdings ( ($SLNH) ) has issued an announcement. Soluna Holdings reported a significant financial performance for the third quarter of 2025,...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SLN	$6.32	-1.86%	302.37K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SLN	$6.32	-1.9%	302.37K
3
4
5
6

SLN

SLN

Latest News for SLN

Get Silence Therapeutics Plc Data in Excel

Get Silence Therapeutics Plc Data in Excel